Why the study?
Does dabigatran etexilate improve outcomes compared to vitamin K antagonists and parenteral anticoagulants in patients requiring treatment or prevention of thromboembolic diseases?
Population
Patients requiring treatment or prevention of thromboembolic diseases, including venous thromboembolism…
Comparison
Dabigatran etexilate vs Vitamin K antagonists and parenteral…
Design
Review
Authors
Loading...
May support dabigatran as convenient oral option for post-orthopedic VTE prophylaxis; leaves open its role versus vitamin K antagonists.
Does dabigatran etexilate improve outcomes compared to vitamin K antagonists and parenteral anticoagulants in patients requiring treatment or prevention of thromboembolic diseases?
Dabigatran etexilate is a promising oral anticoagulant that offers a predictable effect without the need for routine monitoring, potentially providing significant advantages over traditional vitamin K antagonists.
Schulman et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: